CHEVY CHASE, Md., Sept. 17 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced that David M. Mott has joined the firm as General Partner. Mr. Mott, a top biotechnology executive who led industry giant MedImmune to the largest biotech acquisition to date when it was bought by AstraZeneca Plc in 2007, will focus on biotechnology and specialty pharmaceutical investing within NEA’s east coast healthcare practice.
